BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] closed the trading session at $13.79 on 12/30/21. The day’s price range saw the stock hit a low of $13.57, while the highest price level was $13.995. The company report on December 3, 2021 that BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 11 newly-hired employees inducement options to purchase an aggregate of 84,000 shares of BioCryst common stock on November 30, 2021 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
The options have an exercise price of $12.06 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.
The stocks have a year to date performance of 85.10 percent and weekly performance of -0.36 percent. The stock has been moved at -15.24 percent over the last six months. The stock has performed 14.34 percent around the most recent 30 days and changed -4.04 percent over the most recent 3-months.
If compared to the average trading volume of 2.80M shares, BCRX reached to a volume of 2189925 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BioCryst Pharmaceuticals Inc. [BCRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $19.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 10, 2021. The new note on the price target was released on August 06, 2021, representing the official price target for BioCryst Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $21, while Cantor Fitzgerald analysts kept a Overweight rating on BCRX stock.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.64, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 21.64.
BCRX stock trade performance evaluation
BioCryst Pharmaceuticals Inc. [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.36. With this latest performance, BCRX shares gained by 14.34% in over the last four-week period, additionally sinking by -15.24% over the last 6 months – not to mention a rise of 83.87% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 62.20, with the RSI for the last a single of trading hit 68.98, and the three-weeks RSI is set at 57.19 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 12.91, while it was recorded at 13.78 for the last single week of trading, and 14.04 for the last 200 days.
BioCryst Pharmaceuticals Inc. [BCRX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -952.90 and a Gross Margin at +90.59. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -1026.35.
Return on Total Capital for BCRX is now -131.36, given the latest momentum, and Return on Invested Capital for the company is -195.22. Return on Equity for this stock declined to -1,925.37, with Return on Assets sitting at -71.69. Additionally, BCRX Total Debt to Total Capital is recorded at 114.21, with Total Debt to Total Assets ending up at 46.24.
Reflecting on the efficiency of the workforce at the company, BioCryst Pharmaceuticals Inc. [BCRX] managed to generate an average of -$743,146 per employee. Receivables Turnover for the company is 1.16 with a Total Asset Turnover recorded at a value of 0.07.BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 1.90.
Earnings per share (EPS) analysis for BioCryst Pharmaceuticals Inc. [BCRX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 17.10%.
BioCryst Pharmaceuticals Inc. [BCRX]: Insider Ownership positions
There are presently around $1,419 million, or 58.50% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 15,330,858, which is approximately -0.972% of the company’s market cap and around 1.30% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 12,710,818 shares of the stock with an approximate value of $174.14 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $128.47 million in BCRX stock with ownership of nearly 0.779% of the company’s market capitalization.
Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 98 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 9,022,010 shares. Additionally, 93 investors decreased positions by around 10,800,396 shares, while 34 investors held positions by with 83,775,648 shares. The mentioned changes placed institutional holdings at 103,598,054 shares, according to the latest SEC report filing. BCRX stock had 31 new institutional investments in for a total of 1,929,572 shares, while 27 institutional investors sold positions of 1,498,740 shares during the same period.